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Abstract: The global impact of cancer emphasizes the importance of developing innovative, 
effective and minimally invasive therapies. In the context of superficial cancers, the development of 
a multifunctional nanoparticle-based system and its in vitro and in vivo safety and efficacy 
characterization are, herein, proposed as a proof-of-concept. This multifunctional system consists 
of gold nanoparticles coated with hyaluronic and oleic acids, and functionalized with epidermal 
growth factor for greater specificity towards cutaneous melanoma cells. This nanoparticle system is 
activated by a near-infrared laser. The characterization of this nanoparticle system included several 
phases, with in vitro assays being firstly performed to assess the safety of gold nanoparticles 
without laser irradiation. Then, hairless immunocompromised mice were selected for a xenograft 
model upon inoculation of A375 human melanoma cells. Treatment with near-infrared laser 
irradiation for five minutes combined with in situ administration of the nanoparticles showed a 
tumor volume reduction of approximately 80% and, in some cases, led to the formation of several 
necrotic foci, observed histologically. No significant skin erythema at the irradiation zone was 
verified, nor other harmful effects on the excised organs. In conclusion, these assays suggest that 
this system is safe and shows promising results for the treatment of superficial melanoma. 
Keywords: multifunctional nanoparticles; gold nanoparticles; targeted therapy; photothermal 
therapy; superficial tumors; melanoma; experimental models 
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1. Introduction 
Cancer is a worldwide scourge and one of the most feared diseases. Over the last few 
decades, its incidence has been increasing, probably as a consequence of lifestyle changes, 
as well as increased life expectancy [1,2]. Melanoma, in turn, is a complex malignant tu-
mor originated from melanocytes, and it is generally located at the skin level (i.e., cutane-
ous melanoma) although, in a smaller percentage, it can also develop in the mucosa, retina 
and meninges (i.e., non-cutaneous melanoma) [3]. Despite presenting a low incidence, 
melanoma is reported as the most aggressive type of skin tumor, with a high associated 
mortality rate each year [1,3,4]. 
Although several differentiated approaches have been used to treat melanoma over 
the last years, increased tumor-targeted properties, better efficacy profiles, and less side 
effects are essential to improve the outcomes [5,6]. In this segment, photothermal therapy 
(PTT) emerges as a highly promising strategy, once it implies minimal invasion in com-
parison to other currently available therapies, presents a safe profile, and allows a faster 
patient recovery [7]. Briefly, PTT is a precise spatial-temporal technique causing local hy-
perthermia with tissues temperature ranging from 41 to 47°C [8,9] in tumor cells after 
irradiation with light beams [10,11]. This therapy is mostly studied for treatment of super-
ficial tumors due to the light limited ability of deeply penetrating into the tissues. An op-
tion to increase the therapeutic value of this technique includes the use of near-infrared 
(NIR) radiation, which is less absorbed by the tissues, allowing to achieve higher tissue 
depth during tumor treatment [11,12]. 
The use of gold nanoparticles (GNPs) in PTT have demonstrated promising results 
as photothermal enhancers, due to their plasmonic tunable properties [13] and surface 
functionalization [14,15]. When administered directly into the tumor (i.e., intra-tumoral 
injection), GNPs show higher accumulation and tumor residence compared to systemic 
routes (e.g., tail vein intravenous (i.v.) injection) [16]. The addition of targeting moieties 
and ligands to GNPs by physical adsorption of coating polymers or linkers, also promotes 
a more localized and selective action [17–19]. 
To evaluate the toxicity and efficiency of antitumoral therapies, pre-clinical studies 
still depend greatly on animal models [20,21]. Several cancer models have been developed 
[22,23] being murine models the most frequently used [24]. Moreover, xenograft models 
are widely preferred, as they allow the transplantation of human cancer cells into mice 
[25,26]. Human melanoma xenograft models show advantages over other models, such as 
the possibility to control tumor growth and experimental points, by injecting cells through 
a standardized technique [27], and the ability to mimic the histological and genetic char-
acteristics of the original tumors [21]. Further, there is a vast list of well-established cell 
lines characterized from different tumor types for these animal models [26,28,29]. The 
A375 human melanoma cell line is most commonly used in xenograft models, due to its 
successful implementation [29–32], both for local orthotopic tumor development through 
intra-dermal (i.d.) administration [33], and metastases (e.g., lungs and brain), when ad-
ministered i.v. [34]. 
This study reports a proof-of-concept for assessing the in vitro and in vivo toxicity, 
and efficacy profile of a previously developed and partly characterized multifunctional 
hybrid nanoparticle system, developed for NIR-mediated PTT [15,35], in mice induced 
melanoma model upon inoculation with A375 human melanoma cells, which overexpress 
multiple receptors [36,37], including CD44 and epidermal growth factor (EGF) receptors 
[38–41]. This gold nanoparticle-based system coated with hyaluronic (HA) and oleic acids 
(OA), includes EGF as ligand, EGF-conjugated HAOA-coated GNPs. The coupling of HA 
and EGF at nanoparticle surface aimed to improve the in vivo efficiency of the GNPs, by 
specifically targeting CD44 [42] and EGF [40] receptors, respectively. 
These in vitro and in vivo assays were performed in three phases: 1) safety evaluation 
of the GNP formulation; 2) safety evaluation of laser exposure in severe combined im-
mune-deficient (SCID) hairless mice model; and 3) efficacy evaluation of the multifunc-
tional hybrid system in melanoma tumors inoculated in SCID hairless mice by comparing 
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the effect of using the laser irradiation alone or combined with the in situ injection of hy-
brid nanoparticles. 
2. Materials and Methods 
2.1. Materials 
Gold (III) chloride trihydrate (HAuCl4·3H2O), hyaluronic acid (HA) sodium salt from 
Streptococcus equi (MW 7000–250,000 g/mol), oleic acid (OA) (MW 282.46 g/mol), trypsin, 
fetal bovine serum (FBS), and penicillin/streptomycin were all supplied from Sigma-Al-
drich (Steinheim, Germany). Dulbecco's modified Eagle medium (DMEM) was supplied 
by Biowest (Nuaillé, France). The human keratinocyte cell line, HaCat, the human mela-
noma cell line, A375, and the murine melanoma cell line, B16F10, were provided by Cell 
Line Service GmbH (Eppelheim, Germany). Recombinant human epidermal growth fac-
tor (EGF) was purchased from Life Technologies (Waltham, MA, USA). The water used 
in all the experiments was purified through a Millipore system (Millipore, Burlington, 
MA, USA). All the remaining chemicals and substrates used were of analytical grade. 
Intramuscular administration of a mixture of ketamine (Ketamidor®, Richter Pharma, 
Wels, Austria) and chlorpromazine (Largactil®, Laboratórios Vitória, S.A., Amadora, Por-
tugal) (10:2 v/v) at a dose of 2 mL/kg was used as anesthetic protocol for the in vivo exper-
iments. 
2.2. Preparation and Characterization of EGF-conjugated HAOA-coated GNPs 
The multifunctional hybrid system, EGF-conjugated HAOA-coated GNPs, was pre-
pared as previously and fully described [15,35,43]. Briefly, uncoated GNPs were produced 
based on the addition of an aqueous solution containing ascorbic acid, silver nitrate, and 
rosmarinic acid, all of them acting as reducing agents of the gold salt, in substitution of 
toxic chemicals commonly used like cetyl trimethylammonium bromide (CTAB). Then, 
the uncoated GNPs reacted with the coating mixture of HA and OA with a final concen-
tration of 0.5 mg/mL. Later, EGF peptide (10 µg/mL) was added to the formulation and 
allowed to interact with HAOA-coated GNPs for 30 min under magnetic stirring (at 800 
rpm). EGF-conjugated HAOA-coated GNPs were stored for 24 h at 4 °C, protected from 
light, and afterwards centrifuged at 10,900 × g for 10 min (Hermle Labortechnik Gmbh, 
Wehingen, Germany) to remove unbound peptides. Finally, EGF-conjugated HAOA-
coated GNPs were frozen, lyophilized for 24 h at −50.0 ± 2.0 °C, in FreeZone 2.5 L Benchtop 
Freeze Dry System (Labconco, Kansas City, MO, USA) and stored at −20 °C until the day 
of the experiments. 
Subsequently, uncoated, HAOA-coated and EGF-conjugated HAOA-coated GNPs 
were characterized in terms of mean particle size and polydispersity index (PdI) (samples 
diluted in water, 2:10) through dynamic light scattering (DLS) (Zetasizer Nano S; Malvern 
Instruments, Malvern, UK), and zeta potential (samples diluted in phosphate buffer saline 
(PBS), according USP30 and at pH 7.4, 2:10) by electrophoretic mobility technique 
(Zetasizer Nano Z; Malvern Instruments, Malvern, UK), in 3 series of 11 measurements of 
each analyzed sample. 
The morphology of GNPs was evaluated by atomic force microscopy (AFM) analysis. 
Succinctly, 40 µL of sample were placed on a freshly cleaved mica surface and allowed to 
dry overnight before analysis. Images were acquired by Multimode 8 HR coupled to Na-
noscope V Controller (Bruker, Coventry, UK), using peak force tapping and ScanAssist 
mode. Tip model used was scanasyst-air 0.4 N/m, Bruker. 
The absorbance spectra of the EGF-conjugated HAOA-coated GNPs were also ob-
tained by UV–visible spectroscopy (Shimadzu UV-160A; Shimadzu Europa GmbH, Duis-
burg, Germany). 
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2.3. In vitro Safety Assays on HaCat, A375, and B16F10 Cell Lines 
The cytotoxicity of uncoated, HAOA-coated and EGF-conjugated HAOA-coated 
GNPs was evaluated in three cell lines: healthy human keratinocytes (HaCat), human mel-
anoma cells (A375) and murine melanoma cells (B16F10). These commercial cell lines are 
well established, widely used and characterized in the literature, namely, in terms of 
membrane receptors. HaCat [44] and A375 [45] cells are known for their high expression 
of EGFR while, in contrast, B16F10 cells express low levels of this receptor [46]. Further-
more, the three cell lines have been associated with the presence of CD44 membrane re-
ceptors [47], with the lowest expression in HaCat cells and the highest in B16F10 cells. Cell 
lines were grown in DMEM with glucose (4500 mg/L), supplemented with 10% FBS and 
100 IU/mL penicillin and 100 µg/mL streptomycin (Invitrogen; complete medium). Cells 
were preserved at 37 °C under a 5% CO2 atmosphere and cultures were checked and main-
tained every 2–3 days, until achieving a confluence of about 80%. 
Primarily, the cell lines were incubated with increasing concentrations of uncoated 
and HAOA-coated GNPs (25, 50, 75, and 100 µM). These concentrations were based on 
the content of gold. Afterwards, the cytotoxicity of the final formulation, i.e., EGF-conju-
gated HAOA-coated GNPs, was evaluated at the maximum concentration tested in pre-
vious assays. The incubation period was 24 h for all assays. 
The cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay [48]. Succinctly, cells were seeded in 96-well plates (200 
µL) at 5 × 104 cells/mL and allowed to adhere, overnight, in the culture conditions specified 
above. Thereafter, the complete medium was removed, and the cells were incubated at 37 
°C under a 5% CO2 atmosphere for 24 h with GNPs. After the incubation period, medium 
was discarded, and cells were washed two times with PBS. Afterwards, 50 µL of MTT at 
a concentration of 0.5 mg/mL in incomplete medium were added to each well, and plates 
were incubated for 4 h at 37 °C under a 5% CO2 atmosphere. Then, to solubilize the form-
azan crystals, 100 µL of dimethyl sulfoxide (DMSO) were added to each well and plates 
were shaken for 10–15 min. Finally, absorbance was measured in a microplate reader at 
570 nm (BioTek ELx800; BioTek Instruments, Inc., Winooski, VT, USA). The cell viability 
was evaluated by determining the percentage of viable cells (                (%) =
   
   
× 100, where ODt is the optical density of the cells incubated with the tested formu-
lations and ODc is the optical density of the control cells, corresponding to 100% cell via-
bility). 
In addition to the evaluation of cytotoxicity, the presence of the GNPs in A375 cells, 
the same ones used in the xenograft model reported in the following section, was ad-
dressed by atomic force and optical microscopy. Experimental details are presented in 
Supplementary Materials. 
2.4. Human Melanoma Xenograft Model 
This study was conducted using immunosuppressed mice for T and B cells, and hu-
man melanoma A375 cell line (ATCC® CRL-1619™), in the animal facilities of the Faculty 
of Pharmacy, University of Coimbra. 
Hairless 42 days-old male SCID mice (SHO®, SCID Hairless Outbred, code: 474, 
Charles River, Barcelona, Spain) were selected for the establishment of melanoma xeno-
grafts models. This animal model tends to reduce formation of metastases and delay cell 
growth, as demonstrated for the transformed A375 cell line with lung tropism due to the 
presence of natural killer (NK) cells [29]. Animals were allowed to adapt to the laboratory 
conditions for 7 days before testing, maintained with food and water ad libitum and kept 
at 22.0 ± 1.0 °C with controlled 12 h light/dark cycle. After this period, the cells were inoc-
ulated in the fold-back of the animal neck at a concentration of 1 × 106 A375 cells/ mouse 
in 200 µL of PBS pH 7.4, as described in the literature [49].  
Cells were cultured according to the previous section and, at the day of the injection 
(tumor induction day), were treated with a Versene solution (Gibco®, Thermofisher, New 
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York, USA) and NaCO3 (Gibco®, Thermofisher, New York, USA) for alkalinization, and 
were harvested with trypsin and ethylenediaminetetraacetic acid (EDTA). Then, cells 
were centrifuged at 800 × g for 5 min (Eppendorf AG, Hamburg, Germany) and suspended 
in PBS at pH 7.4 for posterior injection in mice. 
The animals were monitored twice a week for weight control, body conditions (body 
condition score—BCS), behavior and signs of tumor progression. The size of the tumors 
and rate of growth were measured using a caliper, until reaching palpable tumor size. A 
minimum tumor volume of approximately 5–10 mm3 was required for inclusion in the 




where length is the largest diameter and width is the smallest diameter perpendicular to 
the length. 
2.5. Photothermal Therapy 
2.5.1. Laser Irradiation Procedure and Treatment Evaluation in SCID Mice 
In order to assess the safety of the laser exposure alone, at an initial phase, and the 
efficacy of the treatment with laser irradiation combined with the EGF-conjugated 
HAOA-coated GNPs, different groups of healthy and melanoma-bearing SCID hairless 
mice were created (Figure 1). The animals were divided as follows: (i) for safety evaluation 
of the laser exposure, six mice without tumors were randomly distributed in two groups: 
1) exposed to 5 min laser irradiation (n = 3), and 2) exposed to 10 min laser irradiation (n 
= 3); (ii) for evaluation of the efficacy of different treatments, mice with palpable tumors 
were randomly assigned to: 1) control group (i.e., no treatment) (n = 3); 2) 5 min laser 
irradiation (n = 3); 3) intra-tumoral injection of EGF-conjugated HAOA-coated GNPs fol-
lowed by exposure to the 5 min laser irradiation (n = 4); and 4) intra-tumoral injection of 
EGF-conjugated HAOA-coated GNPs followed by 10 min laser irradiation (n = 3). In 
Groups 3 and 4, EGF-conjugated HAOA-coated GNPs were reconstituted in PBS at the 
time of administration and injected at the tumor site (i.t.) at a concentration, per mouse, 
of 20 mg/kg of nanoparticles in 100 µL. The GNPs dose was selected based on gold con-
centration, which corresponds to about 1.25 mg/kg. Moreover, it considered the in vitro 
data obtained here and in previous works [15,35], where concentrations up to 80 µM of 
gold did not show significant toxicity. 
The NIR laser (JDSU L4-2495-003 coupled to a source Laserpak ARO-485-08-05) used 
in these experiments had a wavelength of 811 nm and 2.5 W/cm2 irradiance at the target. 
The time of exposure was chosen based on our previous in vitro results [50] and consid-
ered exposure times and irradiation doses found in the literature [51,52] as well as the 
exposure limits in guidelines for the use of NIR radiation [53,54]. 
All animals exposed to laser irradiation were previously anesthetized, which in the 
case of the animals also treated with GNPs occurred 4 h after the injection with EGF-con-
jugated HAOA-coated GNPs. This 4 h time frame was adopted based on the cell internal-
ization time necessary for the same type of GNPs, previously reported by our group [35]. 
Moreover, additional studies to evaluate the presence of the GNPs in the A375 cell line 
were carried out and revealed the presence of these particles upon 4 h of incubation (See 
Figures S1 and S2). The laser beam was applied in the center of the tumors. The animals 
were continuously monitored during the irradiation time (5 or 10 min), and until recover-
ing the righting reflex. Photographs and body weights were also registered before and 
after laser irradiation procedure. 
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Figure 1. Illustrative representation of the different groups created to assess: (a) the safety of the laser exposure; and (b) 
the anti-cancer efficacy of the treatments. (c) Experimental setup. 
2.5.2. In vivo Evaluation of Safety and Efficacy from the Photothermal Therapy Proce-
dure 
During irradiation, animals were closely monitored to ensure that no burns were in-
duced. Furthermore, before and immediately after laser exposure, mice were evaluated 
for possible formation of erythema, at the irradiation zone, by colorimetry (a*, AU) (Mi-
nolta Chroma meter CR-300; Konica Minolta Sensing Americas, Inc., Ramsey, NJ, USA). 
At 24 h post treatment, all animals were sacrificed, according to the applicable animal 
welfare principles. The size and volume of the tumors were registered before and 24 h 
after treatment. Of notice, while the size of the tumors before the treatments was measured 
still in the animal, accounting also the skin and other tissues surrounding the tumor, the 
tumor size after treatments was measured after their excision, accounting only the tumor 
mass. 
In addition to tumors, internal organs (i.e., lungs, kidneys, liver, spleen, and heart) 
were also excised, weighted, measured, and prepared for histological evaluation. The tis-
sue index for each organ was calculated based on the organ and animal weight by apply-
ing the equation:              =  
            
           
× 100 [55]. 
The tissue for analysis was fixed in 10% formalin, paraffin embedded, and cut into 
five-micrometer sections for hematoxylin-eosin staining (H&E staining). Slices were ex-
amined under an Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan), im-
ages were taken using an Olympus U-TV1X-2 color camera and the extent of tumor ne-
crosis was analyzed with Olympus analySIS® software (Olympus Corporation, Tokyo, Ja-
pan). 
2.6. Statistical Analysis 
The cell viability of in vitro assays was expressed as mean ± standard deviation (SD) 
and the statistical analysis was evaluated by two-way ANOVA followed by Tukey’s mul-
tiple comparisons test. The average weights of the groups of animals with and without 
tumors was described as mean ± standard error of the mean (SEM), and the values were 
compared through a Student’s t-test for independent (unpaired) samples. Differences in 
animal weight over time were assessed through a two-way ANOVA followed by Dun-
nett’s multiple comparisons test. The statistical analysis of the erythema was assessed by 
a one-way ANOVA followed by Dunnett’s multiple comparison test, assuming that the 
control group was kept unchanged for erythema (difference of 0). Lastly, tissue indexes 
were compared among the treatment groups using a two-way ANOVA followed by 
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Tukey’s multiple comparisons test. P-values were presented for comparisons whenever 
applicable. A p-value < 0.05 was considered as statistically significant. All statistical anal-
yses were performed using GraphPad Prism version 8.0.2 (GraphPad Software, San Di-
ego, CA, USA). 
3. Results 
3.1. Characterization of EGF-conjugated HAOA-coated GNPs 
The multifunctional hybrid nanoparticles produced for these in vitro and in vivo ex-
periments had similar characteristics to those previously reported by Silva et al. [15,35]. 
EGF-conjugated HAOA-coated GNPs presented spherical morphology (Figure 2) with a 
mean size of 157 nm (PdI ≤ 0.4) and a negative surface charge (−19 ± 9 mV) (Table 1). 
Moreover, the nanoparticles showed a plasmonic absorption band at the NIR range (650–
900 nm), as previously observed [15]. 
Table 1. Mean size, polydispersity index (PdI) and zeta potential of uncoated, HAOA-coated and 







Uncoated GNPs 64 ± 1 0.434 ± 0.007 −24 ± 2 
HAOA-coated GNPs 150 ± 2 0.434 ± 0.014 −40 ± 1 
EGF-conjugated  
HAOA-coated GNPs 
157 ± 5 0.383 ± 0.046 −19 ± 9 
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Figure 2. 3-Dimensional atomic force microscopy images with corresponding cross-secTable 2. In 
Vitro Safety Assays on HaCat, A375 and B16F10 Cell Lines. 
The potential cytotoxicity of uncoated, HAOA-coated and EGF-conjugated HAOA-
coated GNPs was assessed on HaCat, A375 and B16F10 cells by MTT assay. This assay 
relies on the fact that living cells have the ability to transform MTT into formazan crystals, 
reflecting its mitochondrial activity. Since mitochondrial activity is constant for most cell 
lines, it is assumed that variations in cell viability are reflected in the amount of formazan 
crystals formed [56]. 
In a first phase, cell viability was evaluated in the presence of increasing gold-based 
concentrations of uncoated and HAOA-coated GNPs, ranging from 25 to 100 µM. Then, 
the cell viability of the final formulation, i.e., EGF-conjugated HAOA-coated GNPs, was 
also evaluated at 100 µM. Results are depicted in the following figures (Figure 3, 4, and 
5). 
Regarding healthy human keratinocytes, cell viability with uncoated GNPs was sim-
ilar to that of the controls (≥ 94%), regardless of the concentrations tested. Despite preserv-
ing cell viability unchanged at the lowest concentration (25 µM), HAOA-coated GNPs at 
50, 75, and 100 µM caused a significant reduction of about 26% (p < 0.05) on cell viability. 
Conversely, EGF-conjugated HAOA-coated GNPs at 100 µM produced a non-statistically 
significant changes in HaCat cell viability in comparison with uncoated and HAOA-
coated GNPs at the same concentration. 
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Figure 3. Cell viability (%) of HaCat cell line 24 h after incubation with uncoated and HAOA-
coated GNPs at different concentrations, and EGF-conjugated HAOA-coated GNPs at 100 µM. *p < 
0.05, **p < 0.01 and ***p < 0.001 comparing to HAOA-coated GNPs at 25 µM. $p < 0.05 and $$$$p < 
0.0001 comparing to uncoated GNPs in the same concentrations. Data are presented as mean value 
± SD, n ≥ 3. 
With regard to the A375 cell line, similarly to what happened in HaCat cells, un-
coated GNPs did not affect cell viability regardless of the concentrations tested. By its turn, 
for HAOA-coated GNPs a slight reduction on cells viability at all concentrations studied 
was observed. This decrease was statistically significant (p < 0.05) when compared to un-
coated GNPs at each respective concentration. In addition, there was no noticeable loss of 
cell viability for EGF-conjugated HAOA-coated GNPs at 100 µM. 
 
Figure 4. Cell viability (%) of A375 cell line 24 h after incubation with uncoated and HAOA-coated 
GNPs at different concentrations, and EGF-conjugated HAOA-coated GNPs at 100 µM. $p < 0.05, 
$$p < 0.01 and $$$$p < 0.0001 comparing to uncoated GNPs in the same concentrations. Data are 
presented as mean value ± SD, n ≥ 3. 
While for HaCat and A375 cells, uncoated GNPs were safe in all concentrations, for 
B16F10 cells a slight reduction on cell viability was attained: 17% and 13%, when compar-
ing to control cells at the higher concentrations tested, 75 and 100 µM, respectively. 
HAOA-coated GNPs slightly affected B16F10 cell viability but, in this case, for all tested 
concentrations. By its turn, for EGF-conjugated HAOA-coated GNPs at 100 µM, a reduc-
tion in B16F10 cell viability of approximately 28% was exhibited. 
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Figure 5. Cell viability (%) of B16F10 cell line 24 h after incubation with uncoated and HAOA-
coated GNPs at different concentrations, and EGF-conjugated HAOA-coated GNPs at 100 µM. *p < 
0.05 and **p < 0.01 comparing to uncoated GNPs at 25 µM. ##p < 0.01 and ###p < 0.001 comparing 
to uncoated GNPs at 50 µM. $p < 0.05 and $$p < 0.01 comparing to uncoated GNPs in the same 
concentrations. Data are presented as mean value ± SD, n ≥ 3. 
When comparing cell viability for the different formulations at 100 µM in the three 
cell lines tested, overall, B16F10 was the most affected cell line following incubation with 
GNPs (Figure 6). 
 
Figure 6. Comparative cell viability (%) of HaCat, A375 and B16F10 24 h after incubation with 
uncoated, HAOA-coated GNPs and EGF-conjugated HAOA-coated GNPs at 100 µM. **p < 0.01 
and ****p < 0.0001 comparing with the effect of the same type of particles on HaCat cell line. ###p < 
0.001 and ####p < 0.0001 comparing with the effect of the same type of particles on A375 cell line. 
Data are presented as mean value ± SD, n ≥ 3. 
3.2. Human Melanoma Xenograft Model 
All mice were monitored from 60 to 90 days, depending on the tumor growth rate, 
and showed normal water and food intake, respiratory activity, posture (independently 
of the presence or size of the tumor), and mobility, confirming that the animal welfare was 
not compromised. The weight was registered throughout the study until sacrifice, and no 
significant (p < 0.05) weight variations were observed over time. The group of animals 
without tumors presented an average weight of 29.0 ± 0.4 g (27.3 ± 0.5 g to 30.5 ± 3.2 g; n = 
6). By its turn, the animals with tumors showed an average weight of 27.6 ± 0.3 g (21.2 ± 
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1.6 g to 30.1 ± 0.7 g; n = 13). These differences in overall weight were already present before 
the xenograft induction, during the adaptation period. 
The variation of tumors volume and time of appearance after cell inoculation in mice 
was high, ranging from 5 to 1000 mm3, and from two weeks to two months, respectively. 
Despite this fact, SCID mice were monitored twice a week, during all in vivo experiment, 
and have shown stable body conditions with a BCS > 3. 
No visible micro- or macrometastases of melanoma were found in lungs and there 
were no size variations of these organs between the control and tested groups. Due to the 
variability in tumor volumes among the groups, differences between the tumors were 
only compared within the same animal, before and after treatment. 
3.3. In Vivo Evaluation of Safety and Efficacy from the Photothermal Therapy Procedure 
The degree of erythema was evaluated by colorimetry, analyzing the difference in a* 
(AU) before and after laser irradiation. A large variation between animals in each group 
was attained; the control group (without tumor and nanoparticles) showed a mean differ-
ence of a* value of 1.2 ± 1.0 up to 2.7 ± 0.4 after 5 and 10 min of laser irradiation, respec-
tively. In presence of the tumor, the difference of the value of a* was very similar among 
animals after laser irradiation, confirming the safety of the laser source used for healthy 
and tumoral tissues. In the case of the tumor group dosed with nanoparticles, the differ-
ence of a* value increased to 2.8 ± 0.4 and 4.3 ± 1.3 after 5 and 10 min of laser irradiation, 
respectively. Nanoparticle local administration suggested a hypothetic concentration of 
the generated heat in the target area. 
After animal euthanasia, the tumors were isolated and measured in order to compare 
the possible size reduction-effect between the different treatment groups (Figure 7). Alt-
hough, in the control group, the average tumor size did not change within the 24 h be-
tween the application of the treatment and the sacrifice of the animals from the treated 
groups, mice treated with both nanoparticles and laser showed a reduction on the tumor 
volume. Mice treated with EGF-conjugated HAOA-coated GNPs and 5 min laser exposure 
showed an average tumor reduction of 81.1 ± 12.6%. In comparison, when applying the 
same treatment with nanoparticles, but increasing the laser exposure to 10 min, the aver-
age tumor reduction was 43.1 ± 29.4%. For the tumor group exposed only to 5 min laser 
irradiation, there was no overall change in terms of tumor volume, before and after irra-
diation. 
 
Figure 7. Tumor volume reduction of the different test groups, including control or no treatment, 
and after respective treatments, namely, 5 min laser irradiation, EGF-conjugated HAOA-coated 
GNPs + 5 min laser irradiation and EGF-conjugated HAOA-coated GNPs + 10 min laser irradia-
tion. Data are presented as mean value ± SEM, n ≥ 3. 
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Regarding the histological analysis, several necrotic foci were observed in tumor 
samples from each treated group, in comparison to control group. Tumors exposed to 5 
and 10 min laser irradiation combined with EGF-conjugated HAOA-coated GNPs showed 
signs of coagulative necrosis (Figure 8). On the other hand, on tumors exposed to laser 
irradiation alone for 5 min (without local injection of nanoparticles), few morphological 
changes (< 30% extended necrosis) were observed. 
 
Figure 8. Histological images (H&E staining) of the tumors from the four different groups of animals: control (no treat-
ment), 5 min laser irradiation, EGF-conjugated HAOA-coated GNPs + 5 min laser irradiation and EGF-conjugated HAOA-
coated GNPs + 10 min laser irradiation. Scale bar: 100 µm. 
Both the control and treated groups showed similar morphology and size of the in-
ternal organs, namely lungs, kidneys, liver, spleen, and heart. The average tissue indexes 
for each group included in this study are described in Table 2. Overall, there were no 
relevant differences in the tissue indexes of the organs between groups. 
Table 2. Average tissue indexes of male hairless severe combined immune-deficient (SCID) mice 
for each treatment group. Data are presented as mean value ± SEM, n ≥ 3. 
Group of mice 
Tissue Index 
Lung kidney Liver Spleen Heart 
Without tumor + 5 min laser 
irradiation 
8.1 ± 0.2 13.4 ± 0.1 24.1 ± 0.1 3.8 ± 0.1 7.5 ± 0.1 
Without tumor + 10 min laser 
irradiation 
9.0 ± 0.1 14.0 ± 0.1 25.0 ± 1.2 3.7 ± 0.6 8.3 ± 0.3 
Control (With tumor no Treatment) 8.8 ± 0.8 13.2 ± 1.1 24.4 ± 1.8 4.6 ± 0.2 8.0 ± 0.5 
With tumor + 5 min laser irradiation 8.5 ± 0.3 13.3 ± 0.4 23.3 ± 0.6 4.0 ± 0.3 8.0 ± 0.3 
With tumor + EGF-conjugated 
HAOA-coated GNPs + 5 min laser 
irradiation 
7.9 ± 0.1 13.1 ± 0.1 25.9 ± 0.6 4.1 ± 0.2 6.6 ± 0.1 
With tumor + EGF-conjugated 
HAOA-coated GNPs + 10 min laser 
irradiation 
7.7 ± 0.5 13.5 ± 0.6 24.7 ± 0.9 4.8 ± 0.2 7.5 ± 0.3 
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Attending the histology of the different organs (i.e., heart, kidney, liver, spleen, and 
lung) no morphological changes were observed when comparing animals from different 
groups (Figure 9). 
 
Figure 9. Histological images (H&E staining) of lung, kidney, liver, spleen and heart of three different groups of animals: 
animals with tumor, no treatment; with tumor + 5 min laser irradiation; and with tumor + EGF-conjugated HAOA-coated 
GNPs + 5 min laser irradiation. All images are representative of the harvested organs, which showed no inter-group his-
tological alterations. Scale bar: 250 µm. 
4. Discussion 
This proof-of-concept study for melanoma assessed the in vitro safety of a GNP for-
mulation, as well as the safety of NIR laser irradiation (811 nm) exposure in a SCID hair-
less mice melanoma model. Additionally, the efficacy of laser irradiation combined with 
nanoparticles was evaluated for treatment of melanoma in SCID hairless mice. All animals 
showed no abnormal behavior or change of posture associated to suffering, neither any 
significant weight loss over time, confirming that the animal welfare was not compro-
mised. 
The use of xenograft models are often associated with some variation in tumor 
growth and evolution [21]. As reported in this study, and also in other publications [57,58], 
the xenograft model showed different tumor growth rates and, consequently, high varia-
tion in tumor size, which extended the follow-up interval (60–90 days). It is hypothesized 
that high variability depends on distribution of the cells within the tissues after injection, 
time of vascularization of the injected area, and natural variability between animals, such 
as mentioned by others [58]. Moreover, it is believed that adaptative and innate immunity 
of the animals can play a role on xenograft development. For instance, natural killer cells 
are reported by their limiting action over the growth and establishment of human cells 
lines in immunodeficient strains, having been associated with delayed tumor growth and 
increased variability [29]. Due to tumor growth variability, treatments were administered 
to the animals at different times, when individual tumor volumes required for inclusion 
in the study where achieved. Despite this, the existence of tumors with different volumes 
was unavoidable, even within the same treatment group, reinforcing the need to evaluate 
treatment efficacy through the tumor volume reduction. However, factors such as the tu-
mor volume prior to treatment, the administered dose of the nanoparticles and radiation 
applied, must be taken into account in this evaluation. Moreover, at the time of treatment 
the animals had not the same exact age which is a limitation of the xenograft models. 
Additionally, xenograft models require the use of immunocompromised mice [21,29], 
which limits the natural mimicking of the immune system. Finally, the animals did not 
show any lesions in lungs or liver, suggesting that the inoculation of tumor cells success-
fully led to localized melanoma, without metastasis. 
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The EGF-conjugated HAOA-coated GNPs used in this study were partly character-
ized regarding physico-chemical features, in vitro biocompatibility, and cell internaliza-
tion mechanism in our previous studies [15,35]. The nanoparticles synthesized for this 
study had similar characteristics, with mean size from 150 to 200 nm, negative surface 
charge, and spherical morphology. The GNPs size based on the AFM technique also con-
firmed the results obtained by DLS technique. 
To evaluate the potential cytotoxicity of GNP formulations in our study, MTT assays 
were performed on healthy human keratinocytes (HaCat), human melanoma cells (A375) 
and murine melanoma cells (B16F10). Uncoated GNPs proved to be safe in all cell lines. A 
slight reduction on cell viability was observed for the murine melanoma cell line and at 
the two highest concentrations tested. Nevertheless, cell viability remained always above 
80%. On the other hand, and despite preserving cell viability above 70%, when coated and 
bio-conjugated with EGF, the GNPs showed a higher impact in all cell lines, promoting, 
in most cases, a reduction of cell viability when compared to uncoated and non-function-
alized nanoparticles. A possible cause for this reduction in cell viability may be the fact 
that the size of HAOA-coated GNPs and EGF-conjugated HAOA-coated GNPs is about 
double when compared to uncoated GNPs. This greater size may cause a physical “as-
phyxia” effect in cells, as also reported by others [16,59–61]. The precise mechanisms be-
hind cytotoxicity data might be related to differential receptor expression influencing par-
ticle internalization, and different sensitivity to physicochemical features of the particles 
(namely, size and surface charge). The GNPs herein used are coated with HA and further 
conjugated with EGF, which are ligands for CD44 and EGF receptors, respectively, ex-
pressed differently in the cell lines [44–47]. The presence of the particles in A375 cells was 
also assessed to support the protocol followed in vivo in terms of time interval separating 
the GNPs injection and the laser irradiation procedure. A previous work from the group 
showed the entrance of similar GNPs into the peri-nuclear area of A549 cells 1.5 h after 
incubation [35]. Thus, herein, it was considered a longer margin for further in vivo appli-
cation and the internalization was assessed after a period of 4 h of incubation. Once the 
unbound GNPs were removed prior the analyses, two techniques confirm the presence of 
GNPs in the cells, which suggests either their internalization or their binding to the surface 
of the cells. 
Afterwards, the safety of NIR laser irradiation was assessed by testing on healthy 
SCID hairless mice two different exposure times. The dose of gold administered (1.25 
mg/kg) took in consideration the in vitro results attained here, in which concentrations of 
particles up to 80 µM of gold did not show significant toxicity, and this is in agreement 
with previous findings of the group [15,35]. Of notice, the gold dose used herein was lower 
than that reported before involving radiation enhancement [62,63]. The radiation dose and 
time of exposure were selected by taking in consideration irradiation parameters previ-
ously reported for photothermal therapy applications [51,52], and exposure limits im-
posed by law [53,54]. The radiation dose applied was about seven times higher than the 
exposure limit for a NIR source with the same wavelength. Nevertheless, the exposure 
limit corresponds to the maximum level of exposure for which no adverse skin effects are 
expected, but it can be exceeded for diagnostic and therapeutic purposes when the in-
tended benefits of the procedure overcome the potential side effects [54]. Additionally, 
previous in vitro results from the group [50] were taken into account in this decision. None 
of the laser irradiation times compromised the skin integrity or promoted signs of injury, 
either macroscopically or based on histological analysis. The dermis kept its stratified ep-
ithelium and its fibrous structure with sweat glands present in the fatty tissue (hypoder-
mis). In a second phase of this in vivo study, the efficacy of NIR laser irradiation alone or 
combined with the intra-tumoral administration of the EGF-conjugated HAOA-coated 
GNPs was appraised. To evaluate the degree of erythema induced by laser irradiation on 
SCID hairless mice, a chromameter was used to compare the color of the skin before and 
after irradiation. No visible skin burns, nor high degree erythema were observed in any 
animal. With regard to the data on erythema, it should be highlighted that the tumors 
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developed in the fold-back of the animals’ neck but they grew in different rates, and prob-
ably with different deepness. Consequently, it was hypothesized that the vascularity and 
irrigation of the tumors could have varied, influencing the results obtained in the color-
imetry technique. 
Overall, in vivo results showed a significant reduction in the volume of melanoma 
tumor at 24 h-post treatment. The control group did not show any tumor volume changes, 
contrary to the animals treated both with EGF-conjugated HAOA-coated GNPs and NIR 
laser using different exposure times, or submitted to laser irradiation during 5 min. The 
effect of 5 min laser irradiation on tumor volume was not conclusive, since it was tested 
in a small number of animals, and each animal responded differently to the irradiation. 
Any increase in the tumor volume could be, for example, a consequence of an inflamma-
tory process induced by the laser irradiation. 
The most promising results in this study were observed with the 5 min laser irradia-
tion combined with EGF-conjugated HAOA-coated GNPs, which led to a tumor reduction 
of approximately 81%. Furthermore, the results observed for the group of animals treated 
with the 10 min laser irradiation combined with EGF-conjugated HAOA-coated GNPs 
showed a tumor reduction of around 43%. Several factors may have contributed to this 
reduction. The GNPs reach their maximum absorption upon laser irradiation with a spe-
cific wavelength, promoting local hyperthermia of the tissues. It is described that this local 
effect can lead to an irreversible cell damage caused by the disruption of cell membrane 
permeability and protein denaturation [8,9]. Nonetheless, studies on the molecular mech-
anism behind the antitumoral effect of these multifunctional hybrid nanoparticles are still 
under way. Moreover, the combination of polymeric coatings and bio-conjugation could 
probably minimize the interactions of the nanoparticles with macrophages, that range 
from 0% to 30% in the melanoma tissue [64]. That could lead to a reduction of nanoparticle 
phagocytosis by these cells, and thus increasing the available intra-tumoral nanoparticle 
content to ligate to tumoral cells [65]. 
The safety of EGF-conjugated HAOA-coated GNPs was not yet studied in vivo. As 
performed by other authors [66], all animals received the same dose of nanoparticles 
based on their body weight, regardless the tumor volume, despite an intra-tumoral ad-
ministration has been used. For instance, the animals treated with EGF-conjugated 
HAOA-coated GNPs in combination with 5 min laser irradiation presented an average 
volume prior treatment of about forty times smaller than the group of animals treated 
with the same system for 10 min. This difference in tumor volume between the two groups 
may be one of the explanations for the lower reduction in tumor volume in the case of 
treatment of GNPs followed by laser irradiation for 10 min (43% vs. 81%). This comparison 
of results suggests that other existing variables, not yet studied, might influence the eval-
uation of the treatment effect based only on tumor volume reduction. Examples of these 
variables include: tumor physiology; tumor stage (i.e., as the tumor stage advances, the 
prognosis gets worse and the tumor becomes more difficult to treat); and the nanoparticle 
dose adjustment based on the tumor volume [67]. Lastly, if the photothermal effect is en-
hanced by the nanoparticles targeted effect to the melanoma cells and if the dose of the 
nanoparticles is not proportional to the tumor volume, then tumors with different vol-
umes will not be exposed to a proportional amount of nanoparticles, and thus affecting 
the extent of the hyperthermia. 
In terms of histological analysis, tumors that received nanoparticles and were ex-
posed to NIR laser showed coagulative necrosis, in contrast with the tumors not treated. 
The histological analysis of tumoral samples from the groups receiving GNPs did not 
show the presence of GNPs, despite a quantity of particles administered in situ, which 
might be related with the resolution of the optical microscope and the contrast of the im-
ages upon the staining of the samples. Further studies should clarify particle distribution 
in tumor samples. The tumoral samples from treated animals had a pale H&E staining, 
when compared to non-treated animals, which may indicate a loss of tumoral cytoplas-
matic and nuclear content [68]. Tumors treated only with laser irradiation for 5 min 
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showed histological changes, namely necrosis (< 30%). The coagulative necrosis observed 
in the treated tumors could also result from the denaturation of the tissue structural pro-
teins caused by the photothermal effect, as previously reported by other studies [69,70]. 
These results were observed 24 h after NIR treatment, which provides information about 
the immediate treatment efficacy, in accordance to that reported by others [70]. Neverthe-
less, further studies with longer periods of monitoring after the treatment must be carried 
out to evaluate other parameters such as particle biodistribution, potential cytotoxicity, 
and inflammatory and immune responses, among others. 
Finally, to evaluate and compare the toxicity of the methodologies tested, tissue in-
dexes of the multiple organs collected and their histological results were examined. Data 
on tissue indexes showed no significant differences for individual organs among animals 
without and with tumors, neither among animals receiving different treatments. Similar 
results are supported by the histological analysis of the multiple organs, which showed 
no abnormal morphology of the tissues, regardless of the test group in which the animal 
was included. The use of EGF-conjugated HAOA-coated GNPs proved to highly enhance 
the photothermal effect in vivo, without affecting the normal function of the organs nor 
causing any inflammatory systemic response in the 24 h period after nanoparticles admin-
istration. 
5. Conclusions 
In conclusion, this proof-of-concept study suggests that the multifunctional hybrid 
nanoparticle system characterized herein can be a promising new therapeutic strategy for 
localized melanoma. This therapeutic approach did not show evidence of causing damage 
to normal skin structure, which indicates the nanoparticle system selectivity towards the 
melanoma tissues, although further research is necessary to clarify the molecular mecha-
nism underpinning this system. This study also unveils the potential of a unique multi-
functional hybrid system with different targeting moieties to approach other localized su-
perficial tumors, such as squamous cell carcinoma, mammary gland tumor, among others. 
Supplementary Materials: The following are available online at www.mdpi.com/2218-
273X/11/4/511/s1, Figure S1: AFM height images of A375 cells alone (control) and after 4 h of incu-
bation with different GNP formulations. Additional height and peak force error images showed 
with more detail cells incubated with HAOA−coated GNPs leading to hypothesize the presence of 
GNPs aggregates in the surface (arrow) as well as inside of the cell (circle), Figure S2: Representative 
images of A375 cells alone (control) and after 4 h of incubation with different GNP formulations at 
40x magnification. The GNPs appear highly aggregated as darker structures, which seem to be in 
the surface (arrow) as well as inside of the cell (circle). Scale bar, 75 µm. 
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